2. Search Result
Search Result
Results for "

ABHD6 inhibitor

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-132246
    WWL123 analogue-1

    		MAGL Neurological Disease
    WWL123 analogue-1 is an analogue of WWL123. WWL123 is a potent and selective ABHD6 inhibitor with an IC50 of 430 nM . WWL123 crosses the blood-brain-barrier and inhibits ABHD6 in brain parenchyma. ABHD6 blockade by WWL123 exerts an antiepileptic effect in Pentylenetetrazole (PTZ)-induced epileptiform seizures and spontaneous seizures in R6/2 mice .
    WWL123 analogue-1
  • HY-152148
    JZP-MA-11

    		MAGL Neurological Disease
    JZP-MA-11 is a positron emission tomography (PET) ligand targeting the endocannabinoid α/β-hydrolase domain 6 (ABHD6) enzyme. JZP-MA-11 selectively inhibits ABHD6 with an IC50 value of 126 nM. JZP-MA-11 can cross the blood-brain barrier (BBB). [18F]JZP-MA-11 has the potential for preclinical evaluation targeting the brain ABHD6 in mice and nonhuman primate (NHP) .
    JZP-MA-11
  • HY-100337
    WWL70
    2 Publications Verification

    		 MAGL Neurological Disease
    WWL70 is a selective alpha/beta hydrolase domain 6 (ABHD6) inhibitor with an IC50 of 70 nM.
    WWL70
  • HY-114926
    KT185

    		MAGL Neurological Disease
    KT185 is an orally-bioavailable, brain-penetrant and selective ABHD6 inhibitor, with an IC50 0.21 nM in Neuro2A cells .
    KT185
  • HY-120215
    KT203

    		MAGL Metabolic Disease
    KT203 is a potent and selective inhibitor of α/β-hydrolase domain containing 6 (ABHD6), with an IC50 of 0.31 nM in Neuro2A cells .
    KT203
  • HY-120177
    KT182

    		MAGL Others
    KT182 is a potent and selective inhibitor of α/β-hydrolase domain containing 6 (ABHD6), with an IC50 of 0.24 nM in Neuro2A cells .
    KT182
  • HY-117722
    JW 618

    		MAGL Others
    JW 618 is a selective ABHD6 inhibitor, with IC50s of 38 and 13 nM for mouse and rat ABHD6 .
    JW 618
  • HY-116212
    JCP-170

    		MAGL Cancer
    JCP-170, a substituted chloroisocoumarin, is an ABHD6 inhibitor. JCP-170 robustly and reproducibly inhibits metastatic seeding of the murine cell line 0688M and both human pancreatic ductal adenocarcinoma (PDAC) cell lines .
    JCP-170
  • HY-152152
    JZP-MA-13

    		MAGL Neurological Disease
    JZP-MA-13 is a selective α/β-hydrolase domain 6 (ABHD6) inhibitor with an IC50 of 392 nM. JZP-MA-13 shows no inhibition of MAGL, ABHD12, FAAH, or other serine hydrolases. JZP-MA-13 is a positron emission tomography (PET) ligand for in vivo imaging of the ABHD6 .
    JZP-MA-13
  • HY-124314
    LEI-106

    		DAGL MAGL Metabolic Disease
    LEI-106 is a potent, dual sn-1-Diacylglycerol lipase α (DAGL-α)/ABHD6 inhibitor with an IC50 of 18 nM for DAGL-α and a Ki of 0.8 μM for ABHD6. LEI-106 inhibits the hydrolysis of [ 14C]-sn-1-oleoyl-2-arachidonoyl-glycerol, the natural substrate of DAGL-α, with a Ki of 0.7 μM .
    LEI-106
  • HY-18544
    AA38-3

    		MAGL FAAH Metabolic Disease
    AA38-3 is a serine hydrolase (SH) inhibitor. AA38-3 can inhibit three SHs, ABHD6, ABHD11, and FAAH .
    AA38-3
  • HY-110178
    WWL123

    		MAGL Inflammation/Immunology
    WWL123, a carbamate-based compound, is a potent and selective ABHD6 inhibitor. WWL123 can be used for research of inflammation, metabolic disorders (obesity and type II diabetes mellitus) and epilepsy .
    WWL123
  • HY-126031
    (R)-KT109

    		DAGL Others
    (R)-KT109 is a highly potent inhibitor of diacylglycerol lipase β (DAGLβ) with an IC50 of 0.79 nM and effectively blocks DAGLα-mediated hydrolysis of 1-stearoyl-2-arachidonoyl-sn-glycerol. Additionally, it demonstrates inhibitory activity against α/β-hydrolase domain-containing protein 6 (ABHD6) with an IC50 of 2.51 nM, exhibiting greater potency for DAGLβ, DAGLα, and ABHD6 compared to its (S) isomer, (S)-KT109.
    (R)-KT109
  • HY-125143
    ABC34

    		MAGL Metabolic Disease
    ABC34 is an inactive control compound of JJH260. ABC34 does not inhibit the fluorophosphonate reactivity or fatty acid esters of hydroxy fatty acid (FAHFA) hydrolysis activity of AIG1. ABC34 can inhibit both ABHD6 and PPT122 .
    ABC34
  • HY-101457
    JZP-430

    		MAGL Metabolic Disease
    JZP-430 is a potent, highly selective, irreversible inhibitor of α/β-hydrolase domain 6 (ABHD6) with an IC50 of 44 nM, exhibits ~230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL) .
    JZP-430
  • HY-120171
    DH-376

    		DAGL MAGL Metabolic Disease
    DH-376 is a potent diacylglycerol lipase inhibitor with pIC50 values of 8.6 and 8.9 for ABHD6 and DAGLα, respectively. DH-376 prevents fasting-induced refeeding of mice . DH-376 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    DH-376
  • HY-126031A
    (S)-KT109

    		Endogenous Metabolite Others
    (S)-KT109 is an inhibitor of diacylglycerol lipase β (DAGLβ) with low inhibitory activity (IC50 = 39.81 nM). (S)-KT109 has relatively low inhibitory activity against DAGLα-mediated hydrolysis of 1-stearoyl-2-arachidonoyl-sn-glycerol (IC50 = 794.3 nM). (S)-KT109 also has relatively low inhibitory activity against α/β-amidase domain-containing 6 (ABHD6) (IC50 = 630.9 nM) .
    (S)-KT109

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: